MGTA News and Press, Magenta Therapeutics Inc. From 11/04/21

-- Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma -- -- Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease -- --...

Magenta Therapeutics , Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company’s Ch...

Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a fireside chat at the 2021 Cantor Virtual Glo...

Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative condition...

–  Phase 1/2 clinical trial expected to open in Q4 2021 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) – Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing nov...

Gainers: Ascendis Pharma (NASDAQ:ASND) +25%, Zomedica (NYSE:ZOM) +15%, ABVC BioPharma (OTCQB:ABVC) +15%, BeyondSpring (NASDAQ:BYSI) +13%, Cortexyme (NASDAQ:CRTX) +12%. Losers: Aditxt (NASDAQ:ADTX) -29%, Quanterix (NASDAQ:QTRX) -12%, Doxim...

Magenta Therapeutics (NASDAQ:MGTA): Q2 GAAP EPS of -$0.32 beats by $0.05. Ended Q2 2021 with approximately $207.8 million in cash, cash equivalents and marketable securities, and updates guidance that cash reserves are expected to fund the company’s operating plan into Q3 2023. Press R...

–  Progress in addressing the FDA’s recommendations regarding bioassay and dose escalations to clear the current clinical hold on the company’s Investigational New Drug Application to initiate MGTA-117 Phase 1/2 clinical trial – – Enroll...

Magenta Therapeutics ([[MGTA]] -6.3%) continues to trade lower after a sharp drop in value in the pre-market on its announcement that the FDA issued a clinical hold letter on its Phase 1/2 trial for MGTA-117 in acute myeloid leukemia ((AML)) and myelodysplastic syndrome ((MDS)).In a...

Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patie...